Medistim

Earnings Release • Aug 20, 2025

Financial results for the second quarter and first half of 2025 for Medistim ASA

Financial results for the second quarter and first half of 2025 for Medistim ASA

Another strong quarter for sales revenues with 16.7 % growth, ending at MNOK 169.1 (MNOK 144.9). Record sales revenue for the first half year with 25.8 % growth, ending at MNOK 350.6 (MNOK 278.7).

Currency neutral sales of own products were up 18.7 % for the quarter and 25.4 % for the first half.

Strong currency neutral growth for the quarter in AMERICAS and APAC, up 32.9 % and 22.9 % respectively. EMEA down 3.6 %, yet growing 8.1% in the first half.

Third-party distributor sales in Scandinavia increased 3.3 % for the quarter and 21.4 % for the first half year.

Operating profit (EBIT) grew by 31.2 % for the quarter and ended at MNOK 54.1, resulting in 32.0 % EBIT margin (MNOK 41.2, 28.5 % margin). First half operating profit grew 54.5 % ending at a record MNOK 113.3, and 32.3 % EBIT margin (MNOK 73.3, 26.3 % margin).

Recurring sales remained high, but strong capital sales reduce recurring sales in % to 66.8% (74.1 %) compared to the first half last year.

Medistim strengthened its commercial operation by appointing a Chief Commercial Officer and a new VP Sales for AMERICAS.

Solid cash position at quarter end with MNOK 96.4 after paying a dividend of NOK 6.00 per share (NOK 4.5), total MNOK 109.9 in May (MNOK 82.4). No interest-bearing bank loans.